论文部分内容阅读
目的:观察利福布丁、草分枝杆菌F·U·36治疗耐多药肺结核的临床疗效及不良反应。方法:将59例耐多药菌阳性肺结核患者随机分为3组,A组采用3PaVZTh1321 X/15Pa VZTh1321治疗19例(Z用药为6个月);B组采用3RFBPa VZTh1321 X/15RFBPa VZTh1321治疗20例;C组采用3RFBPa VZTh1321 X/15RFBPa VZTh1321+草分枝杆菌F·U·36治疗20例(X为氨基糖苷类药物中的一种,按照链霉素→阿米卡星→卷曲霉素单向耐药顺序选择)。结果:治疗3、6、9、15个月痰菌阴转率A组为42.1%、63.2%、68.4%、73.6%,B组为70.0%、75.0%、85.0%、90.0%,C组为85.0%、90.0%、100.0%、100.0%;三组治疗3个月胸片病灶吸收率分别为21.0%、35.0%、45.0%,空洞吸收率分别为10.5%、25.0%、25.0%。结论:利福布丁联合草分枝杆菌F·U·36治疗耐多药结核病较常用抗结核药在痰菌阴转、胸片病灶吸收和临床症状改善方面效果好,值得临床推广。
Objective: To observe the clinical efficacy and adverse reactions of rifabutin and Mycobacterium phlei F · U · 36 in the treatment of multidrug-resistant pulmonary tuberculosis. Methods: Fifty-nine patients with multidrug-resistant pulmonary tuberculosis were randomly divided into three groups: group A was treated with 3PaVZTh1321X / 15Pa VZTh1321 for 19 months (group Z was 6 months); group B was treated with 3RFBPa VZTh1321X / 15RFBPa VZTh1321 In group C, 20 cases were treated with 3RFBPa VZTh1321X / 15RFBPa VZTh1321 + Mycobacterium phlei F · U · 36 (X was one of aminoglycosides according to streptomycin → amikacin → capreomycin unidirectional resistance Drug order selection). Results: The sputum negative conversion rates in group A were 42.1%, 63.2%, 68.4% and 73.6% at 3, 6, 9 and 15 months, respectively, and were 70.0%, 75.0%, 85.0% and 90.0% respectively in group B, 85.0%, 90.0%, 100.0% and 100.0% respectively. The absorption rates of the three groups were 21.0%, 35.0% and 45.0% respectively at 3 months and the void absorption rates were 10.5%, 25.0% and 25.0% respectively. CONCLUSION: Rifabutin combined with M. gracilis F · U · 36 is effective in treating multidrug-resistant tuberculosis (MDR-TB) compared with commonly used anti-TB drugs in the aspects of sputum negative conversion, chest X-ray absorption and improvement of clinical symptoms, which is worthy of clinical promotion.